Mā te pānga o ngā pyrethroids ka piki ake te mōrearea o te mate a Parkinson nā te taunekeneke ki ngā ira i roto i te pūnaha ārai mate.
Kei te nuinga o ngā wāhi hokohoko ngā piretirongā patu pepeke o te whareAhakoa he paitini ki te roro o ngā pepeke, e kiia ana he haumaru ēnei mō te pa atu ki te tangata e ngā mana whakahaere ā-motu.
Ko ngā rerekētanga ira me te pānga ki ngā patu pepeke te āhua nei he pānga ki te mōrearea o te mate a Parkinson. I kitea e tētahi rangahau hou tētahi hononga i waenga i ēnei āhuatanga mōrearea e rua, e whakaatu ana i te tūranga o te urupare ārai mate ki te whanaketanga o te mate.
E pā ana ngā kitenga ki tētahi akomanga ongā patu pepekee kiia nei ko ngā piretiro, e kitea ana i roto i te nuinga o ngā patu pepeke arumoni o te whare, ā, e piki haere ana te whakamahinga i roto i te ahuwhenua i te mea kua mutu te whakamahi i ētahi atu patu pepeke. Ahakoa he paitini roro ngā piretiro ki ngā pepeke, e whakaaro ana ngā mana whakahaere ā-motu he haumaru ēnei mō te pānga ki te tangata.
Ko tēnei rangahau te tuatahi ki te hono i te pānga o te pyrethroid ki te mōrearea ira mō te mate a Parkinson, ā, e tika ana kia whai ake ngā rangahau, e ai ki te kaituhi matua a Malu Tansi, Ph.D., he ahorangi āwhina mō te mahi tinana i te Kura Hauora o Te Whare Wānanga o Emory.
Kei roto i te rohe kore-waehere o ngā ira MHC II (major histocompatibility complex class II) te momo ira i kitea e te tīma, he rōpū ira e whakahaere ana i te pūnaha ārai mate.
"Kāore mātou i whakaaro ka kitea he hononga motuhake ki ngā piretora," te kī a Tansey. "E mōhiotia ana ka taea e te pānga ohorere ki ngā piretora te whakararu i te pūnaha ārai mate, ā, ko ngā ngota e pā ana ki a rātou ka kitea i roto i ngā pūtau ārai mate; me mārama ake tātou inaianei ki te pānga o te pānga roa ki te pūnaha ārai mate, ā, mā reira ka whakarei ake i tana mahi." Te mōrearea o te mate a Kinson."
"He kaha ngā taunakitanga e whakaatu ana ko te mumura o te roro, ko te kaha rawa rānei o te pūnaha ārai mate, ka whai wāhi pea ki te whanaketanga o te mate a Parkinson. "Ki tā mātou whakaaro, ko te mea pea e tupu ana i konei, ko te pānga o te taiao ki te whakarerekē i te urupare ārai mate o ētahi tāngata, ka whakatairanga i te mumura mau tonu o te roro."
Mō te rangahau, i mahi tahi ngā kairangahau o Emory i arahina e Tansey rāua ko Jeremy Boss, Ph.D., he tumuaki o te Tari Microbiology me te Immunology, me Stuart Factor, Ph.D., kaiwhakahaere o te Emory's Comprehensive Parkinson's Disease Center, me Beate Ritz., MD, Te Whare Wānanga o California, San Francisco. I te mahi tahi me ngā kairangahau hauora tūmatanui i UCLA, Ph.D. Ko te kaituhi tuatahi o te tuhinga ko George T. Kannarkat, MD.
I whakamahia e ngā kairangahau o UCLA tētahi pātengi raraunga whenua o California e kapi ana i te 30 tau o te whakamahinga o ngā patu pepeke i roto i te ahuwhenua. I whakatauhia e rātou te pānga i runga i te tawhiti (te wāhi mahi me te wāhi noho o te tangata) engari kāore i ine i ngā taumata patu pepeke i roto i te tinana. E whakaarohia ana ka tere te pirau o ngā piretiro, inā koa ka pāngia e te rā, me te haurua-ora i roto i te oneone mai i ngā rā ki ngā wiki.
I roto i ngā tāngata 962 o Central Valley o California, ko te momo MHC II noa i honoa ki te pānga ki ngā patupatu pyrethroid i runga ake i te toharite i whakapiki ake i te mōrearea o te mate a Parkinson. Ko te momo ira tino mōrearea (ngā tāngata takitahi e mau ana i ngā ira mōrearea e rua) i kitea i roto i te 21% o ngā tūroro e pangia ana e te mate a Parkinson me te 16% o ngā mana whakahaere.
I roto i tēnei rōpū, kāore te pānga ki te ira, ki te pyrethroid rānei anake i tino whakanui ake i te mōrearea o te mate a Parkinson, engari nā te whakakotahitanga i whakanui ake. Ki te whakatauritea ki te toharite, ko te hunga i pāngia e ngā pyrethroid, ā, i mau i te momo mōrearea nui rawa atu o te ira MHC II, he 2.48 ngā wā nui ake te mōrearea ki te whakawhanake i te mate a Parkinson i te hunga he iti ake te pānga, ā, i mau i te momo mōrearea iti rawa atu o te ira. Kāore te pānga ki ētahi atu momo patupatu, pērā i te organophosphates, te paraquat rānei, e whakanui ake i te mōrearea i te ara kotahi.
Kua honoa e ngā rangahau ira nui ake, tae atu ki a Factor me āna tūroro, ngā rerekētanga ira MHC II ki te mate a Parkinson. He mea whakamiharo, he rerekē te pānga o te rerekētanga ira kotahi ki te mōrearea o te mate a Parkinson i roto i te hunga Pākehā/Pākehā me te iwi Haina. He tino rerekē ngā ira MHC II i waenga i te tangata takitahi; nō reira, he mea nui tā rātou i roto i te kōwhiringa o ngā whakawhitinga okana.
Kua whakaatuhia e ētahi atu whakamātautau ko ngā rerekētanga ira e pā ana ki te mate a Parkinson e pā ana ki te mahi a ngā pūtau ārai mate. I kitea e ngā kairangahau i roto i te 81 o ngā tūroro mate a Parkinson me ngā mana whakahaere Pākehā mai i Te Whare Wānanga o Emory, ko ngā pūtau ārai mate mai i te hunga he nui te mōrearea o ngā rerekētanga ira MHC II mai i te rangahau o California i whakaatu i te nui ake o ngā ngota MHC.
Ko ngā ngota MHC te pūtake o te tukanga "whakaaturanga antigen" ā, koinei te kaha akiaki e whakahohe ana i ngā pūtau-T me te whakauru i te toenga o te pūnaha ārai mate. Ka piki ake te whakaaturanga MHC II i roto i ngā pūtau marino o ngā tūroro mate a Parkinson me ngā mana hauora, engari ka kitea te urupare nui ake ki te wero ārai mate i roto i ngā tūroro mate a Parkinson me ngā momoira mōrearea nui ake;
I whakatau ngā kaituhi: "E kī ana ā mātou raraunga he pai ake pea ngā tohu koiora pūtau, pērā i te whakahohenga MHC II, i ngā ngota wairewa i roto i te toto me te wai cerebrospinal hei tautuhi i ngā tāngata e mōrearea ana ki te mate, hei whakauru atu rānei ki ngā whakamātautau o ngā rongoā ārai mate." "Whakamātautau."
I tautokona te rangahau e te National Institute of Neurological Disorders and Stroke (R01NS072467, 1P50NS071669, F31NS081830), te National Institute of Environmental Health Sciences (5P01ES016731), te National Institute of General Medical Sciences (GM47310), te Sartain Lanier Family Foundation, me te Michael J. Foxpa Kingson Foundation for Disease Research.
Wā tuku: Pipiri-04-2024